EloraTZP Shows Up to 23.3 Percent Weight Loss in Phase 2b Trial

Phase 2b Trial Results for EloraTZP

Eli Lilly reported phase 2b trial data for its investigational medication EloraTZP at the 2026 annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. The drug combines eloralintide with tirzepatide (TZP) to target multiple metabolic pathways.

The 48-week study evaluated 367 adults living with type 2 diabetes and overweight or obesity. Across all tested doses, the combination met primary and secondary trial goals for weight reduction and blood sugar management.

• Trial participants had an average starting weight of 105.4 kg (232.4 pounds).
• Baseline glycated hemoglobin (HbA1c) averaged 8.1% across the study cohort.
• Treatment involved two separate pen injections across four dosing combinations.

Weight and Blood Sugar Outcomes Across Doses

EloraTZP produced dose-dependent reductions in both body weight and blood sugar over the 48-week evaluation period. Adults taking the lowest dose of 3 mg eloralintide and 5 mg tirzepatide lost an average of 13.2% of body weight, equal to 13.9 kg (30.6 pounds).

Participants receiving that low dose also lowered their HbA1c by an average of 2.2%. Those on the highest dose of 9 mg eloralintide and 15 mg tirzepatide lost an average of 23.3% of their body weight, representing 24.6 kg (54.2 pounds), with an average HbA1c drop of 2.9%.

Targeted Hormonal Mechanisms

EloraTZP pairs a selective amylin receptor agonist with a dual receptor agonist. Eloralintide acts on amylin receptors, mimicking the hormone released by pancreatic beta cells after meals.

Tirzepatide acts on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These three distinct hormone pathways regulate satiety and glucose levels through different physiological channels.

Observed Side Effects and Safety Findings

Gastrointestinal issues represented the most common adverse events recorded during the trial. Most reported symptoms were mild or moderate in severity.

These digestive side effects occurred primarily during the dose escalation phase. Participants in the combination arms reported gastrointestinal symptoms more frequently than participants taking eloralintide or tirzepatide alone.

Context and Study Limitations

These findings reflect mid-stage clinical data rather than final regulatory clearance. The drug remains investigational and is not approved by the Food and Drug Administration (FDA) for commercial use.

Longer trials with larger participant groups are required to evaluate long-term outcomes and safety profiles. Adults managing diabetes should speak with a clinician regarding current approved treatment options.